Risk of stroke, gangrene from ergot drug interactions.
作者信息
Wooltorton Eric
机构信息
CMAJ.
出版信息
CMAJ. 2003 Apr 15;168(8):1015.
Abstract
摘要
相似文献
1
Risk of stroke, gangrene from ergot drug interactions.
CMAJ. 2003 Apr 15;168(8):1015.
2
Threatened gangrene in pregnancy caused by root alkaloids.
J Ir Med Assoc. 1970 Dec;63(402):446-7.
3
Managing ergot-induced gangrene: the anesthesiologist as a key player.
Anesth Analg. 2002 Aug;95(2):409-10, table of contents. doi: 10.1097/00000539-200208000-00032.
4
Vasospastic disorders of the limbs.
Br J Hosp Med. 1978 May;19(5):513-7.
5
COX-2 inhibitors and heart.
Indian Heart J. 2005 Nov-Dec;57(6):772-7.
6
[Studies on fluorescent compounds in drinking water of Blackfoot endemic areas. (2) Isolation and identification of fluorescent compounds].
Taiwan Yi Xue Hui Za Zhi. 1977 Mar;76(3):209-17.
7
[Adverse effects of ergot alkaloids. An important differential diagnosis from asbestos-induced pleuritis].
Lakartidningen. 1996 May 29;93(22):2163-4.
8
[A case of acute ergot poisoning].
Ugeskr Laeger. 1954 Apr 22;116(16):616-7.
9
Selective cyclooxygenase 2 inhibitors and cardiovascular events.
Arthritis Rheum. 2005 Jul;52(7):1968-78. doi: 10.1002/art.21132.
10
Estrogen and stroke: a case for low-dose estrogen.
Menopause. 2006 Sep-Oct;13(5):719-20. doi: 10.1097/01.gme.0000232280.89842.d0.
引用本文的文献
1
identification of drug candidates against COVID-19.
Inform Med Unlocked. 2020;21:100461. doi: 10.1016/j.imu.2020.100461. Epub 2020 Oct 20.
2
The Migraine-Stroke Connection.
J Stroke. 2016 May;18(2):146-56. doi: 10.5853/jos.2015.01683. Epub 2016 May 31.
3
Holy fire in an HIV-positive man: a case of 21st-century ergotism.
CMAJ. 2010 Mar 9;182(4):378-80. doi: 10.1503/cmaj.091362. Epub 2010 Jan 4.
本文引用的文献
1
Fatal ergotism induced by an HIV protease inhibitor.
Headache. 2002 Jul-Aug;42(7):694-5. doi: 10.1046/j.1526-4610.2002.02163.x.
2
Grapefruit juice: potential drug interactions.
CMAJ. 2002 Aug 6;167(3):279-80.
3
St Anthony's fire and living ligatures: a short history of ergometrine.
Lancet. 2002 May 18;359(9319):1768-70. doi: 10.1016/S0140-6736(02)08658-0.
4
Clinically significant drug interactions with agents specific for migraine attacks.
CNS Drugs. 2001;15(2):105-18. doi: 10.2165/00023210-200115020-00003.
5
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Clin Pharmacokinet. 2000 Jan;38(1):41-57. doi: 10.2165/00003088-200038010-00003.
6
Ergotamine in the acute treatment of migraine: a review and European consensus.
Brain. 2000 Jan;123 ( Pt 1):9-18. doi: 10.1093/brain/123.1.9.
7
Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society.
CMAJ. 1997 May 1;156(9):1273-87.
Zotero 插件